Caris Life Sciences, Inc. Common Stock (CAI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.61B
Last updated: Nov 17, 2026 at 11:04 AM ET
Caris Life Sciences, Inc. Common Stock (CAI) Competitors
The companies most similar to Caris Life Sciences, Inc. Common Stock are Ionis Pharmaceuticals (IONS), Axsome Therapeutics (AXSM) and Kodiak Sciences (KOD). By market cap, Caris Life Sciences, Inc. Common Stock ranks 7th of the 13 companies on this page; Cytokinetics (CYTK) is the largest at $7.82B.
Peer Comparison
CAI's revenue growth of 27.0% is above the peer median of 25.9%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Caris Life Sciences, Inc. Common Stock (CAI) | $6.61B | N/A | 5.7x | 9.2% | N/A | 27.0% | 0.00% |
| Ionis Pharmaceuticals Inc (IONS) | $4.84B | N/A | 4.8x | -56.9% | -29.3% | 54.9% | 0.00% |
| Axsome Therapeutics Inc (AXSM) | $7.45B | N/A | 8.6x | -18.2% | -48.1% | 51.9% | 0.00% |
| Kodiak Sciences Inc (KOD) | $7.27B | N/A | N/A | 0.0% | -1481.8% | 0.0% | 0.00% |
| Cytokinetics Inc (CYTK) | $7.82B | N/A | 65.3x | 0.0% | -66.0% | 2357.0% | 0.00% |
| Iovance Biotherapeutics Inc (IOVA) | $3.59B | N/A | 9.1x | -58.2% | N/A | 80.1% | 0.00% |
| CG Oncology, Inc. Common stock (CGON) | $6.65B | N/A | N/A | 0.0% | -21.1% | -3.7% | 0.00% |
| Abivax SA American Depositary Shares (ABVX) | $7.67B | N/A | N/A | 0.0% | -159.6% | -6.8% | 0.00% |
| Cogent Biosciences Inc (COGT) | $4.97B | N/A | N/A | 0.0% | -43.4% | -100.0% | 0.00% |
| Crispr Therapeutics AG (CRSP) | $4.10B | N/A | 155.2x | 0.0% | -20.3% | 1325.0% | 0.00% |
| Erasca Inc (ERAS) | $5.50B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Immunovant Inc (IMVT) | $7.07B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tarsus Pharmaceuticals Inc (TARS) | $3.96B | N/A | 5.4x | -102.9% | -393.6% | 63.9% | 0.00% |
| Peer median | $6.07B | N/A | 8.8x | 0.0% | -48.1% | 25.9% | 0.00% |
Similar Companies
These are the 12 companies most similar to Caris Life Sciences, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Ionis Pharmaceuticals Inc (IONS) | Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California. | IONS competitors |
| Axsome Therapeutics Inc (AXSM) | Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United... | AXSM competitors |
| Kodiak Sciences Inc (KOD) | Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing... | KOD competitors |
| Cytokinetics Inc (CYTK) | Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering... | CYTK competitors |
| Iovance Biotherapeutics Inc (IOVA) | Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness... | IOVA competitors |
| CG Oncology, Inc. Common stock (CGON) | CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070... | CGON competitors |
| Abivax SA American Depositary Shares (ABVX) | Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. | ABVX competitors |
| Cogent Biosciences Inc (COGT) | Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. | COGT competitors |
| Crispr Therapeutics AG (CRSP) | CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. | CRSP competitors |
| Erasca Inc (ERAS) | Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers... | ERAS competitors |
| Immunovant Inc (IMVT) | Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. | IMVT competitors |
| Tarsus Pharmaceuticals Inc (TARS) | Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates... | TARS competitors |
Frequently Asked Questions About CAI
Who are Caris Life Sciences, Inc. Common Stock's main competitors?
The companies most similar to Caris Life Sciences, Inc. Common Stock include Ionis Pharmaceuticals (IONS), Axsome Therapeutics (AXSM), Kodiak Sciences (KOD), Cytokinetics (CYTK) and Iovance Biotherapeutics (IOVA), listed from the closest match.
Who is Caris Life Sciences, Inc. Common Stock's biggest competitor?
Cytokinetics (CYTK) is the largest of the similar companies at $7.82B; Ionis Pharmaceuticals (IONS) is the closest match by business profile, size, sector and industry.
How does CAI stock compare with its competitors?
CAI's P/S is 5.7x against a peer median of 8.8x; its net margin is 9.2% against a peer median of 0.0%.
Which of Caris Life Sciences, Inc. Common Stock's competitors pays a higher dividend?
Caris Life Sciences, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Caris Life Sciences, Inc. Common Stock bigger than its competitors?
No. Caris Life Sciences, Inc. Common Stock is 7th by market cap among the 13 companies on this page; the largest is Cytokinetics (CYTK) at $7.82B.
CAI pages: Overview, Forecast, Financials, Valuation, Competitors